Nebilet Plus (Hydrochlorothiazide, Nebivolol)

Nebivolol and Hydrochlorothiazide, the active ingredients in Nebilet Plus, are a beta‑blocker and thiazide diuretic combination presented as an oral tablet for systemic use. The formulation is indicated for the management of elevated blood pressure in adult patients, helping to achieve target blood pressure levels and reduce cardiovascular risk.

GNH USA supplies Nebilet Plus as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution across.

Nebilet Plus, a combined beta‑blocker and thiazide diuretic, is used in the management of hypertension.

- Essential hypertension: lowers systolic and diastolic blood pressure to target levels - Stage 1 hypertension: provides initial blood pressure control when monotherapy is insufficient - Stage 2 hypertension: offers additive effect to achieve adequate pressure reduction

Nebilet Plus may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Dizziness - Headache - Fatigue - Increased urination

Serious or Rare Side Effects: - Electrolyte imbalance (e.g., hyponatraemia, hypokalaemia) - Severe hypotension - Acute kidney injury - Allergic reactions such as rash or angio‑edema

When prescribing Nebilet Plus, clinicians should observe several safety considerations.

- Blood pressure monitoring: check regularly to avoid excessive hypotension - Renal function assessment: evaluate creatinine and eGFR before and during therapy - Electrolyte surveillance: monitor potassium and sodium levels - Diabetes caution: may mask hypoglycaemia symptoms - Avoid abrupt discontinuation: taper to prevent rebound hypertension - Store at room temperature: keep in original container, protect from moisture and light

Nebilet Plus can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., paroxetine, fluoxetine): increase nebivolol plasma levels - Other antihypertensives (e.g., ACE inhibitors, ARBs): risk of additive hypotension - Lithium: thiazide component may raise lithium concentrations

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may reduce diuretic effect - Potassium‑sparing diuretics or supplements: risk of hyperkalaemia - Beta‑agonist bronchodilators (e.g., albuterol): may diminish bronchodilation